Bevacizumab biosimilar(Jiangsu Aosaikang)

贝伐珠单抗生物类似药（江苏奥赛康）

Report date: 2022/10/10 13:38:47

Base Information

Drug NameBevacizumab biosimilar(Jiangsu Aosaikang)
Drug Alias NameRecombinant anti-VEGF humanized monoclonal antibodyASK-1202AMD-BAK-3008ASK-B1202 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJiangsu Aosaikang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Anke Biotechnology (Group) Co LtdJiangsu Aosaikang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A